Amryt transforms itself with takeover of US pharma firm to develop key drugs
The chance to advance medicines for rare conditions such as EB, or butterfly skin, spurred the company on to make the acquisition
Just over four years ago, Dr Joe Wiley set about building Amryt into a world leader in developing rare and orphan disease drugs. It came about via an unusual route: a reverse takeover of a tiny Dublin-based oil and gas exploration company called Fastnet that was looking for other opportunities. Fast forward four years and Amryt has just finalised a transformational takeover of an American drug company called Aegerion that will catapult it into the...
Subscribe from just 1€
Choose the subscription that is right for you
For the first month
€19.99 Monthly ThereafterSubscribe today
For the first year
€199.99 annually thereafterSubscribe today
For the first 90 days
€55.00 quarterly ThereafterSubscribe today
These offers are not available for current subscribers. Offers and pricing are subject to change without notice.
Terms & Conditions Apply